# A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)

> **NCT06144749** · PHASE1,PHASE2 · RECRUITING · sponsor: **Hillhurst Biopharmaceuticals, Inc.** · enrollment: 9 (estimated)

## Conditions studied

- Anemia, Sickle Cell

## Interventions

- **DRUG:** HBI-002

## Key facts

- **NCT ID:** NCT06144749
- **Lead sponsor:** Hillhurst Biopharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-15
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-06-30
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2026-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06144749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06144749, "A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06144749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*